Revenio Group

Aktiemarkedet ser ikke længere ud til at bekymre sig om iCare og har placeret Revenio-aktien i en rabatkurv. Vi ser dette som en mulighed.

Revenios værdiansættelsesniveau er faldet til et historisk lavt niveau, da der er bekymringer i branchen, især efter Zeiss' grimme nedjustering. Vi anser, at bekymringerne vedrørende Revenio er overdrevne, og vi vurderer, at selskabets regnskabsmeddelelse vil være solidt stigende i år.

14:40

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Revenio's Q3 earnings fell short of our overly optimistic expectations, but on the other hand, the Q4 outlook appears better than we anticipated. There have been no dramatic revisions in the outlook for the coming years, but the market is showing at least small signs of recovery.

We expect the company to achieve good revenue growth, although the weakening US dollar and uncertainty caused by US tariffs are creating difficulties.

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.